Regulated information

2010 annual earnings

Lure (France), April 4, 2011 – Vétoquinol’s Board of Directors, meeting on March 18, 2011, has reviewed the Group’s business and approved its 2010 financial statements.

2010 Revenues grow 11.8%, driven by organic growth

The Vétoquinol Group reports sustained sales growth driven by its “hybrid” business model, supported by a sound level of organic growth.

Arrêté de la feuille de présence (french)

CONVOCATION : assemblée d'actionnaires et de porteurs de parts (french)

Avis de réunion valant avis de convocation.
<br>
Mesdames et Messieurs les actionnaires sont convoqués le vendredi 20 mai 2011 à 15h30, au siège social, 34, rue du Chêne Sainte-Anne, 70200 Lure,
en Assemblée Générale Mixte, à l’effet de délibérer sur l’ordre du jour et les projets de résolutions suivants :

European launch of new Nsaid Cimalgex®

Lure (France), June 14, 2011 – Vetoquinol announces the European launch of CIMALGEX®, a new treatment for pain and inflammation in dogs.

Forcyl®: european launch of new drug

Lure (France), September 29, 2011 – Vétoquinol announces the European launch of Forcyl®, a new drug based on 16% concentrated marbofloxacin allowing the treatment of cattle respiratory infections with a single injection.

Formulaire droit de vote (french)

Formulaire de vote pour l'Assemblée Générale du 20 mai 2011

International expansion and new product launches

Lure (France), July 19, 2011 – Vétoquinol Group sales rose to €139.7 million in the first six months of 2011.

Jacques du Puy appointed Vétoquinol Managing Director

Lure (France), October 12, 2011 – The Vétoquinol Group announces the appointment
of Jacques du Puy as Managing Director.

Net Sales rise 3% to €66.4 Million in the first Quarter of 2011

The Vétoquinol group reported a 3.0% rise in first quarter 2011 net sales to €66.4 million, compared to the same period last year.